RT Journal Article
T1 Insulin-like Growth Factor II Prevents MPP+ and Glucocorticoid Mitochondrial-Oxidative and Neuronal Damage in Dopaminergic Neurons
A1 Claros-Gil, Silvia
A1 Cabrera, Pablo
A1 Valverde, María
A1 Romero-Zerbo, Silvana Yanina
A1 López-González, Manuel Víctor
A1 Shumilov, Kirill
A1 Rivera-Ramírez, Alicia
A1 Pavía-Molina, José
A1 Martín-Montañez, Elisa
A1 García-Fernández, María Inmaculada
K1 Parkinson, Enfermedad de
AB Stress seems to contribute to Parkinson’s disease (PD) neuropathology, probably by dysregulation of the hypothalamic–pituitary–adrenal axis. Key factors in this pathophysiology are oxidative stress and mitochondrial dysfunction and neuronal glucocorticoid-induced toxicity. The insulin-like growth factor II (IGF-II), a pleiotropic hormone, has shown antioxidant and neuroprotective effects in some neurodegenerative disorders. Our aim was to examine the protective effect of IGF-II on a dopaminergic cellular combined model of PD and mild to moderate stress measuring oxidative stress parameters, mitochondrial and neuronal markers, and signalling pathways. IGF-II counteracts the mitochondrial-oxidative damage produced by the toxic synergistic effect of corticosterone and 1-methyl-4-phenylpyridinium, protecting dopaminergic neurons from death and neurodegeneration. IGF-II promotes PKC activation and nuclear factor (erythroid-derived 2)-like 2 antioxidant response in a glucocorticoid receptor-dependent pathway, preventing oxidative cell damage and maintaining mitochondrial function. Thus, IGF-II is a potential therapeutic tool for treatment and prevention of disease progression in PD patients suffering mild to moderate emotional stress.
PB MDPI
YR 2021
FD 2021-12-24
LK https://hdl.handle.net/10630/29909
UL https://hdl.handle.net/10630/29909
LA eng
NO Claros, S.; Cabrera, P.; Valverde, N.; Romero-Zerbo, S.Y.; López-González, M.V.; Shumilov, K.; Rivera, A.; Pavia, J.; Martín-Montañez, E.; Garcia-Fernandez, M. Insulin-like Growth Factor II Prevents MPP+ and Glucocorticoid Mitochondrial-Oxidative and Neuronal Damage in Dopaminergic Neurons. Antioxidants 2022, 11, 41. https://doi.org/10.3390/antiox11010041
NO Proyecto I+D+I Programa Operativo FEDER Andalucía 2014–2020 (UMA18-FEDERJA-004) Junta de Andalucía.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026